Antibody for gastric cancer progresses to Phase III trials
Drug Discovery World
OCTOBER 12, 2023
The company received approvals from the Center for Drug Evaluation (CDE) in China and MFDS in South Korea for the Phase III pivotal trial of Osemitamab in July 2023. The interim safety, clinical pharmacology and efficacy data we presented fostered a productive dialogue with the FDA.
Let's personalize your content